 Michael Clay
Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomarkers, Tumor | 10 | 2024 | 1173 | 1.910 |
Why?
| | Lipoma | 4 | 2022 | 15 | 1.900 |
Why?
| | Soft Tissue Neoplasms | 5 | 2024 | 111 | 1.290 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 4 | 2024 | 64 | 1.260 |
Why?
| | Liposarcoma | 4 | 2024 | 27 | 1.150 |
Why?
| | Rhabdomyosarcoma | 4 | 2022 | 64 | 1.070 |
Why?
| | Adrenal Cortex Neoplasms | 3 | 2023 | 60 | 1.050 |
Why?
| | In Situ Hybridization, Fluorescence | 5 | 2024 | 313 | 0.970 |
Why?
| | Adrenocortical Carcinoma | 2 | 2023 | 63 | 0.910 |
Why?
| | DNA Methylation | 5 | 2024 | 610 | 0.900 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 2 | 2013 | 54 | 0.810 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2013 | 82 | 0.800 |
Why?
| | Tissue Scaffolds | 1 | 2024 | 201 | 0.780 |
Why?
| | Surgical Wound Infection | 1 | 2024 | 283 | 0.740 |
Why?
| | Immunohistochemistry | 7 | 2024 | 1691 | 0.700 |
Why?
| | Extracellular Matrix | 1 | 2024 | 502 | 0.690 |
Why?
| | Fibroma | 1 | 2020 | 22 | 0.660 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 1344 | 0.630 |
Why?
| | Succinate Dehydrogenase | 1 | 2019 | 44 | 0.630 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2019 | 46 | 0.610 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2019 | 72 | 0.590 |
Why?
| | Breast Neoplasms | 3 | 2014 | 2140 | 0.550 |
Why?
| | Kidney Neoplasms | 4 | 2024 | 348 | 0.550 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2016 | 44 | 0.530 |
Why?
| | Gene Amplification | 2 | 2020 | 105 | 0.510 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1688 | 0.510 |
Why?
| | DNA Mismatch Repair | 1 | 2014 | 47 | 0.460 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 33 | 0.450 |
Why?
| | Neoplasms, Second Primary | 1 | 2014 | 106 | 0.420 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2023 | 509 | 0.420 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 61 | 0.420 |
Why?
| | Translocation, Genetic | 1 | 2013 | 96 | 0.420 |
Why?
| | Diagnosis, Differential | 6 | 2024 | 1430 | 0.420 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 192 | 0.390 |
Why?
| | Wilms Tumor | 3 | 2023 | 77 | 0.380 |
Why?
| | Sexually Transmitted Diseases, Viral | 1 | 2010 | 8 | 0.350 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2011 | 34 | 0.350 |
Why?
| | Nuclear Proteins | 4 | 2021 | 659 | 0.350 |
Why?
| | Myometrium | 1 | 2011 | 37 | 0.340 |
Why?
| | Receptor, ErbB-2 | 1 | 2013 | 326 | 0.340 |
Why?
| | Li-Fraumeni Syndrome | 2 | 2021 | 13 | 0.340 |
Why?
| | Anus Neoplasms | 1 | 2010 | 30 | 0.340 |
Why?
| | Uterine Neoplasms | 1 | 2011 | 102 | 0.330 |
Why?
| | Humans | 42 | 2024 | 129248 | 0.300 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 140 | 0.300 |
Why?
| | Genomics | 3 | 2021 | 717 | 0.270 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1555 | 0.270 |
Why?
| | Male | 26 | 2024 | 63501 | 0.260 |
Why?
| | Female | 25 | 2024 | 68543 | 0.240 |
Why?
| | Neoplasms | 4 | 2021 | 2449 | 0.240 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2024 | 200 | 0.240 |
Why?
| | Myoepithelioma | 1 | 2024 | 3 | 0.240 |
Why?
| | Hyphae | 1 | 2024 | 11 | 0.230 |
Why?
| | Epigenesis, Genetic | 3 | 2024 | 616 | 0.230 |
Why?
| | Child, Preschool | 9 | 2024 | 10456 | 0.230 |
Why?
| | Young Adult | 8 | 2024 | 12388 | 0.230 |
Why?
| | Adamantinoma | 1 | 2023 | 5 | 0.220 |
Why?
| | Antineoplastic Agents | 3 | 2023 | 2053 | 0.210 |
Why?
| | Oncogene Fusion | 2 | 2020 | 14 | 0.210 |
Why?
| | Fungi | 1 | 2024 | 135 | 0.210 |
Why?
| | Liver Neoplasms | 2 | 2019 | 640 | 0.210 |
Why?
| | Adult | 14 | 2024 | 35495 | 0.210 |
Why?
| | X-linked Nuclear Protein | 2 | 2020 | 8 | 0.210 |
Why?
| | Meniscus | 1 | 2023 | 21 | 0.200 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2022 | 20 | 0.190 |
Why?
| | Child | 15 | 2024 | 20773 | 0.190 |
Why?
| | Wound Healing | 1 | 2024 | 305 | 0.190 |
Why?
| | Infant | 10 | 2021 | 8975 | 0.190 |
Why?
| | Aged, 80 and over | 5 | 2024 | 7055 | 0.190 |
Why?
| | Neuroblastoma | 2 | 2020 | 151 | 0.190 |
Why?
| | Adolescent | 9 | 2024 | 20303 | 0.180 |
Why?
| | Aged | 8 | 2024 | 22032 | 0.180 |
Why?
| | In Situ Hybridization | 1 | 2021 | 296 | 0.180 |
Why?
| | Mutation | 4 | 2021 | 3710 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 958 | 0.180 |
Why?
| | Immunoglobulin A | 1 | 2022 | 200 | 0.180 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2023 | 140 | 0.180 |
Why?
| | Penetrance | 1 | 2021 | 27 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2023 | 231 | 0.180 |
Why?
| | Orthopedic Procedures | 1 | 2023 | 208 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 812 | 0.180 |
Why?
| | Middle Aged | 10 | 2024 | 31087 | 0.180 |
Why?
| | Whole Genome Sequencing | 1 | 2021 | 129 | 0.180 |
Why?
| | Myofibroma | 1 | 2020 | 4 | 0.180 |
Why?
| | Germ Cells | 1 | 2021 | 59 | 0.170 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 168 | 0.170 |
Why?
| | Xanthogranuloma, Juvenile | 1 | 2020 | 5 | 0.170 |
Why?
| | Introns | 1 | 2021 | 251 | 0.170 |
Why?
| | Tandem Repeat Sequences | 2 | 2017 | 18 | 0.170 |
Why?
| | Exons | 1 | 2021 | 341 | 0.170 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 29 | 0.170 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2020 | 42 | 0.170 |
Why?
| | Receptor, trkA | 1 | 2020 | 16 | 0.170 |
Why?
| | N-Myc Proto-Oncogene Protein | 1 | 2020 | 8 | 0.170 |
Why?
| | Sarcoma, Ewing | 1 | 2021 | 88 | 0.170 |
Why?
| | Phthalazines | 1 | 2020 | 41 | 0.170 |
Why?
| | Computational Biology | 2 | 2021 | 595 | 0.170 |
Why?
| | Osteoarthritis, Knee | 1 | 2023 | 240 | 0.170 |
Why?
| | Lamin Type A | 1 | 2020 | 48 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 332 | 0.160 |
Why?
| | Cell Nucleus | 2 | 2020 | 586 | 0.160 |
Why?
| | Phenotype | 2 | 2020 | 3074 | 0.160 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 90 | 0.160 |
Why?
| | Clonal Evolution | 1 | 2019 | 39 | 0.160 |
Why?
| | Cell Dedifferentiation | 1 | 2019 | 30 | 0.160 |
Why?
| | Mutation, Missense | 1 | 2021 | 317 | 0.160 |
Why?
| | DNA Damage | 1 | 2021 | 383 | 0.150 |
Why?
| | Muscle Neoplasms | 1 | 2018 | 8 | 0.150 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2023 | 305 | 0.150 |
Why?
| | Psychomotor Disorders | 1 | 2018 | 17 | 0.150 |
Why?
| | Patella | 1 | 2018 | 22 | 0.150 |
Why?
| | Neuroendocrine Tumors | 1 | 2019 | 99 | 0.150 |
Why?
| | Scrotum | 1 | 2018 | 26 | 0.150 |
Why?
| | Rhabdoid Tumor | 1 | 2019 | 95 | 0.150 |
Why?
| | Codon, Nonsense | 1 | 2018 | 39 | 0.150 |
Why?
| | Prognosis | 3 | 2022 | 3772 | 0.150 |
Why?
| | ErbB Receptors | 2 | 2022 | 605 | 0.150 |
Why?
| | Craniofacial Abnormalities | 1 | 2018 | 63 | 0.140 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2018 | 432 | 0.140 |
Why?
| | Tumor Burden | 2 | 2017 | 286 | 0.140 |
Why?
| | Mice | 8 | 2022 | 16915 | 0.140 |
Why?
| | Urogenital Abnormalities | 1 | 2018 | 52 | 0.140 |
Why?
| | Immunophenotyping | 1 | 2019 | 310 | 0.140 |
Why?
| | Histone Acetyltransferases | 1 | 2018 | 61 | 0.140 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 584 | 0.140 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 275 | 0.140 |
Why?
| | Heterozygote | 1 | 2018 | 272 | 0.140 |
Why?
| | Fused Kidney | 1 | 2017 | 1 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 8 | 0.140 |
Why?
| | Sarcoma, Clear Cell | 1 | 2017 | 8 | 0.140 |
Why?
| | Fibrosarcoma | 1 | 2017 | 21 | 0.140 |
Why?
| | Beckwith-Wiedemann Syndrome | 1 | 2016 | 6 | 0.140 |
Why?
| | Retrospective Studies | 6 | 2024 | 14455 | 0.130 |
Why?
| | Intellectual Disability | 1 | 2018 | 154 | 0.130 |
Why?
| | Hemangioendothelioma | 1 | 2016 | 15 | 0.130 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2016 | 7 | 0.130 |
Why?
| | Genetic Variation | 1 | 2021 | 938 | 0.130 |
Why?
| | Reproducibility of Results | 2 | 2015 | 3079 | 0.130 |
Why?
| | Ectodermal Dysplasia | 1 | 2016 | 16 | 0.130 |
Why?
| | Scalp | 1 | 2016 | 34 | 0.130 |
Why?
| | Troponin | 1 | 2015 | 50 | 0.120 |
Why?
| | Sarcoma, Kaposi | 1 | 2016 | 76 | 0.120 |
Why?
| | Mismatch Repair Endonuclease PMS2 | 1 | 2014 | 4 | 0.120 |
Why?
| | MutL Protein Homolog 1 | 1 | 2014 | 12 | 0.120 |
Why?
| | MutS Homolog 2 Protein | 1 | 2014 | 14 | 0.120 |
Why?
| | Clone Cells | 2 | 2017 | 262 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2019 | 756 | 0.120 |
Why?
| | Chromosome Aberrations | 2 | 2017 | 148 | 0.120 |
Why?
| | DNA Repair Enzymes | 1 | 2014 | 20 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2276 | 0.110 |
Why?
| | Adenosine Triphosphatases | 1 | 2014 | 161 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1097 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 1946 | 0.110 |
Why?
| | Repressor Proteins | 1 | 2017 | 406 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 385 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 2017 | 635 | 0.100 |
Why?
| | Breast | 1 | 2013 | 153 | 0.100 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2014 | 209 | 0.100 |
Why?
| | Algorithms | 1 | 2020 | 1613 | 0.100 |
Why?
| | Trastuzumab | 1 | 2013 | 101 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 758 | 0.100 |
Why?
| | Mastectomy | 1 | 2013 | 131 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1837 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2014 | 399 | 0.090 |
Why?
| | Disease Management | 1 | 2015 | 588 | 0.090 |
Why?
| | Risk Factors | 2 | 2015 | 9745 | 0.090 |
Why?
| | Epithelioid Cells | 1 | 2011 | 8 | 0.090 |
Why?
| | Genomic Imprinting | 2 | 2023 | 33 | 0.090 |
Why?
| | Kidney | 1 | 2018 | 1385 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4057 | 0.090 |
Why?
| | Animals | 10 | 2023 | 35307 | 0.090 |
Why?
| | Penile Neoplasms | 1 | 2010 | 7 | 0.090 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1143 | 0.090 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2010 | 42 | 0.080 |
Why?
| | DNA, Neoplasm | 1 | 2010 | 158 | 0.080 |
Why?
| | Critical Illness | 1 | 2015 | 757 | 0.080 |
Why?
| | Papillomaviridae | 1 | 2010 | 114 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1199 | 0.080 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1290 | 0.080 |
Why?
| | Mice, Nude | 2 | 2021 | 682 | 0.080 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 428 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2515 | 0.080 |
Why?
| | Liver | 1 | 2016 | 1839 | 0.070 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2010 | 230 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1266 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1446 | 0.070 |
Why?
| | DNA | 2 | 2023 | 1396 | 0.060 |
Why?
| | Rodent Control | 1 | 1985 | 2 | 0.060 |
Why?
| | Leptospira interrogans | 1 | 1985 | 4 | 0.060 |
Why?
| | Leptospirosis | 1 | 1985 | 8 | 0.060 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 625 | 0.060 |
Why?
| | Gene Fusion | 1 | 2024 | 24 | 0.060 |
Why?
| | Diaphyses | 1 | 2023 | 15 | 0.050 |
Why?
| | Occupational Diseases | 1 | 1985 | 138 | 0.050 |
Why?
| | Ulna | 1 | 2023 | 27 | 0.050 |
Why?
| | Activating Transcription Factor 4 | 1 | 2023 | 20 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2023 | 42 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2010 | 898 | 0.050 |
Why?
| | Fibula | 1 | 2023 | 47 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2023 | 148 | 0.050 |
Why?
| | Prospective Studies | 1 | 2014 | 7121 | 0.050 |
Why?
| | Carcinoma, Renal Cell | 1 | 2024 | 180 | 0.050 |
Why?
| | Cellular Senescence | 1 | 2023 | 181 | 0.050 |
Why?
| | Drug Resistance | 1 | 2022 | 166 | 0.050 |
Why?
| | Muscle Development | 1 | 2022 | 103 | 0.050 |
Why?
| | Gene Knock-In Techniques | 1 | 2021 | 53 | 0.040 |
Why?
| | Myositis Ossificans | 1 | 2020 | 3 | 0.040 |
Why?
| | Periosteum | 1 | 2020 | 11 | 0.040 |
Why?
| | Brazil | 1 | 2021 | 154 | 0.040 |
Why?
| | Fasciitis | 1 | 2020 | 12 | 0.040 |
Why?
| | Biopsy | 1 | 2024 | 1091 | 0.040 |
Why?
| | Dasatinib | 1 | 2020 | 54 | 0.040 |
Why?
| | Complement Activation | 1 | 2023 | 381 | 0.040 |
Why?
| | Freezing | 1 | 2020 | 85 | 0.040 |
Why?
| | Autoantigens | 1 | 2022 | 419 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2020 | 148 | 0.040 |
Why?
| | Etoposide | 1 | 2019 | 148 | 0.040 |
Why?
| | Carboplatin | 1 | 2019 | 139 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 631 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2020 | 216 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 350 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 2019 | 78 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 283 | 0.040 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2018 | 45 | 0.040 |
Why?
| | Genotype | 1 | 2023 | 1835 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2018 | 53 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2022 | 848 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 942 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 5736 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2017 | 5 | 0.040 |
Why?
| | Epigenomics | 1 | 2018 | 110 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 476 | 0.040 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2017 | 56 | 0.040 |
Why?
| | Bortezomib | 1 | 2017 | 45 | 0.040 |
Why?
| | Cohort Studies | 2 | 2020 | 5408 | 0.040 |
Why?
| | Genes, p53 | 1 | 2017 | 70 | 0.040 |
Why?
| | Signal Transduction | 2 | 2023 | 4926 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2017 | 88 | 0.030 |
Why?
| | Vincristine | 1 | 2017 | 108 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 131 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2020 | 595 | 0.030 |
Why?
| | Camptothecin | 1 | 2017 | 110 | 0.030 |
Why?
| | Pyrimidinones | 1 | 2017 | 103 | 0.030 |
Why?
| | Stromal Cells | 1 | 2016 | 105 | 0.030 |
Why?
| | High-Throughput Screening Assays | 1 | 2017 | 138 | 0.030 |
Why?
| | Family | 1 | 2020 | 644 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1367 | 0.030 |
Why?
| | Fibroblasts | 1 | 2021 | 947 | 0.030 |
Why?
| | beta Catenin | 1 | 2017 | 223 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2117 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 390 | 0.030 |
Why?
| | Autoantibodies | 1 | 2022 | 1467 | 0.030 |
Why?
| | Precision Medicine | 1 | 2018 | 386 | 0.030 |
Why?
| | Indoles | 1 | 2017 | 384 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1040 | 0.030 |
Why?
| | Leukocyte Transfusion | 1 | 1994 | 2 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2498 | 0.030 |
Why?
| | Pyrazoles | 1 | 2017 | 404 | 0.030 |
Why?
| | Granulocytes | 1 | 1994 | 77 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2017 | 1036 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 459 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 877 | 0.030 |
Why?
| | Mycoses | 1 | 1994 | 71 | 0.030 |
Why?
| | Neutropenia | 1 | 1994 | 136 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 4076 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2020 | 2871 | 0.030 |
Why?
| | Aging | 1 | 2023 | 1774 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 1994 | 275 | 0.020 |
Why?
| | Acute Coronary Syndrome | 1 | 2015 | 267 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 1054 | 0.020 |
Why?
| | United States Department of Veterans Affairs | 1 | 2015 | 623 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 430 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2015 | 846 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 3201 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5439 | 0.020 |
Why?
| | Registries | 1 | 2017 | 1895 | 0.020 |
Why?
| | Michigan | 1 | 1985 | 104 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 1985 | 74 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 10199 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 3966 | 0.010 |
Why?
| | United States | 1 | 2015 | 13828 | 0.010 |
Why?
| | Rats | 1 | 1985 | 5482 | 0.010 |
Why?
| | Aspergillus | 1 | 1994 | 15 | 0.010 |
Why?
| | Candida albicans | 1 | 1994 | 53 | 0.010 |
Why?
| | Candidiasis | 1 | 1994 | 56 | 0.010 |
Why?
|
|
Clay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|